| 000 | 02639cam a2200169 4500 | ||
|---|---|---|---|
| 001 | NMDX7447 | ||
| 008 | 120401t2017 xxu||||| |||| 00| 0 eng d | ||
| 100 | _aNair, S. | ||
| 240 | _aInternational Journal of Ophthalmology | ||
| 245 | _aEfficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients | ||
| 260 | _c2017 | ||
| 500 | _aNMUH Staff Publications | ||
| 500 | _a10 | ||
| 520 | _a<h4><span style="font-size: 10pt;">AIM:<span style="font-weight: normal;"> </span></span><span style="font-size: 10pt;"><span style="font-weight: normal;">To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy.</span></span></h4><h4><span style="font-size: 10pt;">METHODS: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired <em>t</em>-test at the 5% significance level.</span></span></h4><h4><span style="font-size: 10pt;">RESULTS: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (<em>P</em>&lt;0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (<em>P</em>&lt;0.001).</span></span></h4><h4><span style="font-size: 10pt;">CONCLUSION: </span><span style="font-size: 10pt;"><span style="font-weight: normal;">This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.</span></span></h4>&nbsp; | ||
| 856 | _uhttps://www.ncbi.nlm.nih.gov/pubmed/28861351 | ||
| 856 | _uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554844/pdf/ijo-10-08-1251.pdf | ||
| 999 |
_c76343 _d76343 |
||